Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $39.00

Bicara Therapeutics (NASDAQ:BCAX) had its price objective lifted by BTIG Research from $28.00 to $39.00 in a research report released on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

BCAX has been the topic of a number of other reports. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Guggenheim began coverage on Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Finally, The Goldman Sachs Group raised their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $24.28 on Wednesday. Bicara Therapeutics has a 52 week low of $10.30 and a 52 week high of $30.99. The firm’s fifty day moving average is $26.15 and its 200-day moving average is $21.80. The firm has a market cap of $1.61 billion, a PE ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). Sell-side analysts forecast that Bicara Therapeutics will post -3.45 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 18,750 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $524,625.00. Following the completion of the sale, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at $5,082,315.18. This trade represents a 9.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.97, for a total value of $349,625.00. Following the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at approximately $3,632,044.35. The trade was a 8.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 117,200 shares of company stock worth $3,267,100 in the last three months. 13.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Candriam S.C.A. purchased a new stake in Bicara Therapeutics in the first quarter valued at about $4,750,000. UBS Group AG boosted its position in Bicara Therapeutics by 97.4% in the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after purchasing an additional 94,829 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Bicara Therapeutics by 166.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock worth $2,170,000 after purchasing an additional 68,327 shares during the period. Janus Henderson Group PLC increased its stake in shares of Bicara Therapeutics by 26.2% in the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares in the last quarter. Finally, Orbimed Advisors LLC increased its holdings in Bicara Therapeutics by 219.1% in the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after acquiring an additional 458,200 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.